Tag: Gastric cancer

In clinical trials, the most common adverse reactions (≥10%) for patients taking Lonsurf included anemia, neutropenia, fatigue, nausea, and diarrhea. Understanding **what are the common side effects of Lonsurf** is key for patients and caregivers managing this cancer treatment.

In recent clinical trials, the targeted drug trastuzumab deruxtecan (Enhertu) demonstrated a 72% improvement in progression-free survival for certain patients with HER2-positive metastatic breast cancer compared to a different therapy. This innovative medication, which incorporates the chemotherapy payload **Deruxtecan**, represents a significant advancement in oncology by selectively delivering potent treatment directly to cancer cells.